Elsevier Announces the Launch of Open Access Journal: EBioMedicine

AMSTERDAM, November 4, 2014 /PRNewswire/ --

EBioMedicine brings together worlds of basic research and clinical science in a new, open access journal with Cell Press and The Lancet editorial influence 

Elsevier is a world-leading provider of scientific, technical and medical information products and services. Two of its leading brands, Cell Press and The Lancet, have now joined forces to launch a new open access journal, EBioMedicine. The broad-spectrum journal will publish research papers covering the entire breadth of life and health sciences, ranging from basic research to clinical and public/global health science.

EBioMedicine will also place a high priority on rapid publication and seeks to publish a broad range of research study types. In addition, the journal will publish commentaries and viewpoints that enhance the access to and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.

Co-Editorial Director of EBioMedicine, Editor-in-Chief of Cell and CEO of Cell Press, Emilie Marcus commented, "Building a better pipeline between scientific research and improved human health is front and center on the global stage as calls increase for faster translation of publically-funded basic research into effective prevention, diagnosis and treatment of disease. EBioMedicine is designed to be a central player in building this pipeline by creating a forum that brings scientists and physicians together to transform information into action."

"EBioMedicine is a unique endeavor to bridge the gap between the laboratory and the clinic, an opportunity to forge a new kind of knowledge, tacking between understanding and application, science and practice, mechanism and delivery," said Richard Horton, Co-Editorial Director of EBioMedicine and Editor-in-Chief and Publisher of The Lancet.

With two full-time professional Editors in Chief, Dr Duc Le and Dr Julie Stacey, working from within The Lancet and Cell Press offices, this new journal is perfectly poised to facilitate the dialogue and collaboration between basic researchers and clinicians who are at the interface of these two communities.

Anne Kitson, EVP for Health & Medical Sciences journal publishing at Elsevier, added, "We believe that EBioMedicine will become the premier open access publication for where these two communities meet to disseminate ideas and cross-fertilize information, enabling quicker transformation of scientific insights into health improvement."

For more information or to submit an article, go to: http://www.EBioMedicine.com.

First articles have been published and are available through ScienceDirect.

About Open Access Publishing at Elsevier 

Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as over 100 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess.

About Elsevier 

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Hans Zijlstra
Elsevier
+31-20-485-3340
[email protected]

SOURCE Elsevier